AS Latvijas Juras medicinas centrs (ORSE:LJM1R) EBITDA Margin %: -0.36% (As of Dec. 2025)


ORSE:LJM1R AS Latvijas Juras medicinas centrs ORSE:LJM1R
59 GF Score
Price €7.80
GF Value €7.78
! 3 Warning Signs
View Full Analysis

What is AS Latvijas Juras medicinas centrs EBITDA Margin %?

AS Latvijas Juras medicinas centrs ORSE:LJM1R 59 EBITDA Margin % is -0.36% as of Dec. 2025. GuruFocus rates ORSE:LJM1R with a GF Score™ of 59/100 and a GF Value™ of €7.78. The stock has 3 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. AS Latvijas Juras medicinas centrs's EBITDA for the three months ended in Dec. 2025 was €-0.01 Mil. AS Latvijas Juras medicinas centrs's Revenue for the three months ended in Dec. 2025 was €2.51 Mil. Therefore, AS Latvijas Juras medicinas centrs's EBITDA margin for the quarter that ended in Dec. 2025 was -0.36%.


AS Latvijas Juras medicinas centrs  (ORSE:LJM1R) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


AS Latvijas Juras medicinas centrs EBITDA Margin % Related Terms


AS Latvijas Juras medicinas centrs EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for AS Latvijas Juras medicinas centrs's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AS Latvijas Juras medicinas centrs EBITDA Margin % Chart

AS Latvijas Juras medicinas centrs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.25 9.65 -1.81 6.81 7.21

AS Latvijas Juras medicinas centrs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.75 5.85 5.39 5.50 -0.36

ORSE:LJM1R vs HCA, THC, ENSG: EBITDA Margin % Comparison

For the Medical Care Facilities subindustry, AS Latvijas Juras medicinas centrs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AS Latvijas Juras medicinas centrs EBITDA Margin % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, AS Latvijas Juras medicinas centrs's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where AS Latvijas Juras medicinas centrs's EBITDA Margin % falls into.


ORSE:LJM1R
59GF Score
AS Latvijas Juras medicinas centrs ORSE:LJM1R
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AS Latvijas Juras medicinas centrs EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

AS Latvijas Juras medicinas centrs's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0.742/10.288
=7.21 %

AS Latvijas Juras medicinas centrs's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.009/2.509
=-0.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -0.36% mean?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a EBITDA Margin % of -0.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AS Latvijas Juras medicinas centrs and its competitors.
Is AS Latvijas Juras medicinas centrs' EBITDA Margin % too high?
AS Latvijas Juras medicinas centrs' current EBITDA Margin % is -0.36%. Overall, AS Latvijas Juras medicinas centrs has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does AS Latvijas Juras medicinas centrs' EBITDA Margin % compare to HCA and THC?
AS Latvijas Juras medicinas centrs' EBITDA Margin % of -0.36% can be compared against companies in the Healthcare Providers & Services industry. The industry median EBITDA Margin % is 10.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AS Latvijas Juras medicinas centrs and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AS Latvijas Juras medicinas centrs's current EBITDA Margin % is -0.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AS Latvijas Juras medicinas centrs stock overvalued right now?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a current EBITDA Margin % of -0.36%. The stock's GF Value™ is €7.78, compared to a current price of €7.80 — trading 0.3% above its estimated fair value. The current EBITDA Margin % is -0.36%. AS Latvijas Juras medicinas centrs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AS Latvijas Juras medicinas centrs (ORSE:LJM1R), the current EBITDA Margin % is -0.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Overvalued in 2026?

Based on GuruFocus' analysis, AS Latvijas Juras medicinas centrs stock appears to be overvalued. The current stock price of €7.80 is trading 0.3% above its estimated GF Value™ of €7.78.

Key valuation signals for ORSE:LJM1R:

  • EBITDA Margin %: -0.36%
  • GF Value™: €7.78 vs. price of €7.80 (0.3% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the ORSE:LJM1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AS Latvijas Juras medicinas centrs Business Description

Address Patversmes iela 23, Riga, LVA, LV-1005
AS Latvijas Juras medicinas centrs is a private certified medical institution in Latvia providing outpatient and inpatient healthcare services through qualified staff and modern equipment. Its core activities include hospital services, orthopaedic retail, medical and dental practice, human health and residential care, social work activities, and physical well-being services. It operates the Women's Health Clinic, offering gynecological consultations, pregnancy care, diagnostics, postpartum services, gynecological care for girls, and surgery. The centre also provides vaccination, rehabilitation, a Multiple Sclerosis Center, medical commission, home visits, laboratory services, physical medicine and massage, therapeutic procedures, medical treatment, and anesthesia and intensive care.
59GF Score

Get the complete analysis for ORSE:LJM1R

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.80
Price
€7.78
GF Value